Rosch shares drop after profit warning
This article was originally published in Clinica
German company Rosch Medizintechnik's shares lost more than a quarter of their value after the company lowered its earnings outlook for the full year. The company, which develops the INJEX needle-free injection system, attributed the poor results to the fact that German health insurers had not yet agreed to reimburse for the product. Shares in the company reached E13.55 ($11.50), a new 52-week low. This compares with a year-high of E68.